Cleveland biolabs inc (CBLI)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10
Current assets:
Cash and cash equivalents

1,058

1,126

1,487

2,237

2,798

3,617

4,378

4,007

4,586

4,230

4,590

3,932

3,820

6,901

4,051

5,412

10,594

5,918

6,362

3,190

4,256

3,103

7,877

11,103

13,391

10,048

14,312

13,245

19,769

25,652

12,188

13,229

18,111

22,872

25,260

30,996

10,918

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents

-

-

-

-

2,798

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Short-term investments

-

-

-

-

-

-

-

-

-

4,561

-

-

-

8,343

-

-

-

13,701

-

-

-

0

1,269

-

280

305

-

-

-

2,633

-

-

-

-

-

-

-

Short-term investments

360

452

426

396

540

503

956

2,520

3,097

-

5,466

7,524

9,253

-

10,877

10,941

7,382

-

16,151

450

769

-

-

-

-

-

309

305

1,286

-

6,954

8,788

5,520

5,520

31

712

459

Accounts receivable

334

378

210

337

269

251

199

346

372

554

444

427

516

352

1,420

895

1,192

631

366

133

307

267

175

392

414

458

603

1,172

477

41

82

92

806

1,740

412

140

5,382

Receivable for divestiture of Incuron, LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current assets

80

45

67

74

115

103

104

121

251

233

321

292

231

289

603

586

500

442

505

215

248

174

365

477

377

344

590

730

1,136

1,078

1,321

1,324

781

876

963

1,209

991

Total current assets

1,833

2,002

2,192

3,046

3,725

4,476

5,639

6,995

8,308

9,579

10,822

12,176

13,821

15,887

16,953

17,836

19,669

20,693

23,386

4,989

5,581

3,545

9,687

11,973

14,464

11,156

15,816

15,453

22,669

29,405

20,546

23,434

25,219

31,010

26,667

33,058

17,751

Computer equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

557

543

-

Lab equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,754

1,579

-

Furniture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

522

472

-

Property, Plant and Equipment, Gross, Total

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,834

2,595

-

Less accumulated depreciation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,709

1,594

-

Equipment, net

12

15

17

20

23

27

25

27

32

18

18

23

29

37

45

54

66

122

151

182

209

244

287

335

384

457

825

880

910

986

1,084

1,163

1,260

1,084

1,124

1,000

941

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

42

40

37

1,097

859

815

1,699

-

-

-

2,921

-

-

-

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,427

2,843

2,679

-

2,871

1,465

1,541

1,577

-

-

-

-

-

-

-

Intellectual property

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,488

1,162

Other long-term assets

18

18

18

18

30

30

33

33

29

30

30

30

30

30

30

28

26

26

26

41

48

56

65

74

137

159

174

54

61

39

35

34

38

32

332

15

32

Deferred Transaction Costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

775

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investment in Incuron, LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,020

4,268

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

33

-

Assets Noncurrent excluding Property, Plant and Equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

332

1,537

-

Total assets

1,864

2,036

2,228

3,085

3,779

4,534

5,698

7,056

8,369

9,629

10,871

12,230

13,881

15,955

17,029

17,962

19,803

20,880

24,661

6,848

10,677

9,814

12,468

15,226

17,665

14,695

19,688

17,853

25,183

32,010

21,666

24,633

26,518

32,126

28,123

35,596

19,886

Current liabilities:
Accounts payable

266

263

99

274

245

139

120

151

267

201

380

298

379

336

186

144

246

197

623

950

989

1,057

889

719

489

794

1,202

1,194

1,234

1,523

440

671

1,068

909

1,329

655

1,261

Accrued expenses

774

782

441

603

592

694

1,231

1,281

1,355

970

864

1,200

1,185

1,823

1,253

1,383

1,866

1,584

1,822

2,025

2,070

1,804

1,796

2,122

2,972

2,445

3,082

3,021

3,285

2,410

3,613

3,350

2,224

1,686

634

241

136

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

161

105

11

255

466

418

156

356

744

1,086

1,069

2,035

2,450

3,024

3,314

3,844

66

-

-

0

201

349

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

2,107

1,968

Accrued bonuses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

3,321

Accrued warrant liability

44

6

24

60

173

78

241

362

532

1,041

1,027

861

1,071

949

1,348

3,183

2,636

4,048

5,309

5,356

4,547

862

1,861

1,024

1,436

1,241

3,594

4,757

7,553

4,105

7,446

3,022

5,566

7,285

6,013

10,006

25,350

Current portion of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,125

2,836

2,736

2,640

735

481

892

351

-

-

-

-

-

-

-

-

-

-

-

Current portion of capital lease obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

29

50

71

83

80

77

74

71

69

-

64

-

-

-

-

Total current liabilities

1,085

1,052

565

939

1,011

911

1,592

1,796

2,156

2,213

2,272

2,359

2,635

3,109

2,788

4,872

4,854

5,842

10,136

11,635

10,763

6,529

5,668

5,144

6,950

5,985

9,995

11,501

15,171

11,426

15,413

7,111

8,923

9,881

7,976

11,104

30,418

Non-current liabilities

-

-

-

-

-

-

-

-

-

7

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncurrent portion of capital lease obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

7

29

50

78

97

116

134

152

-

-

-

-

Long-term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,135

1,321

1,499

3,479

3,634

6,725

7,121

7,330

-

-

-

-

-

-

-

-

-

-

Non-current liabilities

-

-

-

3

7

8

8

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,107

-

Commitments and contingencies (Note 9)

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

-

-

0

-

-

-

-

0

0

0

Total liabilities

1,085

1,052

565

943

1,018

920

1,601

1,796

2,156

2,220

2,272

2,359

2,635

3,109

2,788

4,872

4,854

5,842

10,136

12,771

12,084

8,028

9,147

8,778

13,675

13,114

17,355

11,552

15,249

11,524

15,530

7,246

9,076

9,881

-

-

32,386

Stockholders’ equity:
Preferred stock, $.005 par value; 1,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 0 shares issued and outstanding as of March 31, 2020 and December 31, 2019

-

-

-

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

-

0

Common stock, $.005 par value; 25,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 11,403,239 and 11,298,239 shares issued and outstanding as of March 31, 2020 and December 31, 2019

56

56

56

56

56

56

56

56

56

56

56

56

54

54

54

54

54

54

53

21

17

14

285

285

254

11

225

224

224

223

179

179

178

178

177

176

144

Additional paid-in capital

-

-

-

-

-

-

-

-

-

163,106

-

-

-

158,773

-

-

-

158,764

-

-

133,235

132,693

134,773

134,201

130,080

125,723

125,398

124,792

124,256

123,864

111,904

111,433

109,726

108,865

108,258

107,298

80,241

Additional paid-in capital

163,666

163,161

163,161

163,161

163,161

163,161

163,161

163,161

163,161

-

163,106

163,106

158,773

-

158,773

158,773

158,771

-

157,774

134,042

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accumulated other comprehensive loss

-642

-568

-582

-574

-584

-611

-588

-565

-510

-516

-521

-539

-497

-564

-407

-409

-407

-408

-465

-425

-450

-380

-201

236

117

307

307

288

454

546

463

125

500

84

-81

160

-30

Accumulated deficit

-167,294

-166,705

-165,998

-165,548

-164,931

-164,058

-163,626

-162,522

-161,671

-160,446

-159,277

-158,016

-152,403

-150,740

-149,508

-150,647

-148,646

-147,978

-145,826

-142,706

-138,261

-133,935

-145,207

-141,111

-137,150

-135,564

-135,199

-131,108

-128,066

-118,301

-121,411

-110,533

-105,454

-100,067

-92,876

-90,184

-96,053

Treasury Stock, at cost; 0 and 158,900, respectively

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

544

906

906

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total Cleveland BioLabs, Inc. stockholders’ deficit

-4,213

-4,055

-3,363

-2,905

-2,298

-1,451

-997

130

1,036

2,199

3,363

4,607

5,927

7,523

8,912

7,771

9,771

9,888

10,629

-9,974

-5,459

-1,607

-10,349

-6,387

-6,697

-9,522

-9,267

-5,802

-3,130

6,333

-8,863

1,205

4,950

9,060

15,477

17,450

-15,698

Noncontrolling interest in stockholders’ equity

4,993

5,039

5,026

5,047

5,059

5,065

5,093

5,129

5,176

5,208

5,235

5,264

5,318

5,322

5,328

5,318

5,176

5,149

3,896

4,051

4,051

3,393

13,670

12,836

10,686

11,103

11,600

12,103

13,064

14,152

14,999

16,182

12,492

13,184

4,669

4,933

3,197

Total stockholders’ equity

779

984

1,663

2,142

2,761

3,614

4,096

5,259

6,213

7,408

8,599

9,871

11,246

12,846

14,240

13,090

14,948

15,037

14,525

-5,923

-1,407

1,786

3,320

6,448

3,989

1,580

2,333

6,300

9,933

20,485

6,135

17,387

17,442

22,245

20,147

22,384

-12,500

Total liabilities and stockholders’ equity

1,864

2,036

2,228

3,085

3,779

4,534

5,698

7,056

8,369

9,629

10,871

12,230

13,881

15,955

17,029

17,962

19,803

20,880

24,661

6,848

10,677

9,814

12,468

15,226

17,665

14,695

19,688

17,853

25,183

32,010

21,666

24,633

26,518

32,126

28,123

35,596

19,886